Clinical trials: FLU
Virus Diseases, Respiratory Tract Diseases
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older
The primary safety objective of this study is to assess the safety of split- virion inactivated H1N1 vaccine with and without adjuvant when administered at the 7.5,15 or 30 mcg dose.
- Conditions
- Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
- Trial name
- NCT00975572
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 30 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg
- Where
- China
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Healthy
Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer
The purpose of this study to evaluate the safety of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) in comparison with Fluarix Prefilled Syringe (inactivated split influenza vaccine) after…
- Trial name
- NCT02330003
- Testing
- IL-YANG FLU Vaccine Prefilled Syringe INJ., Fluarix Prefilled Syringe
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943631
- Testing
- Inactivated H1N1 Vaccine
- Where
- 3 sites in United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Influenza
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent…
- Trial name
- COVID-19 (NCT05519839)
- Testing
- qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant
- Where
- 35 sites in Australia, New Zealand
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Novavax
Enterovirus Infections, Influenza
Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine
Subjects will be recruited and divided into 3 groups: 1. Experimental Group (378 subjects): combined immunization of EV71 vaccine and influenza vaccine; 2. Control Group A (378 subjects): EV71 vaccine only; 3.
- Trial name
- NCT04091880
- Testing
- EV71 vaccine and influenza vaccine, EV71 vaccine, influenza vaccine
- Where
- China
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza A Virus Infection, Swine Flu
A Pilot Study for Collection of Anti-Influenza A Immune Plasma
Background: The influenza A virus can cause infections that lead to fever, cough, muscle aches, diarrhea, and headaches, and can even be fatal in some people.
- Trial name
- NCT00984451
- Testing
- Plasma collection following infection or vaccination with influenza A
- Where
- 12 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
The objective of this study is to document the residual burden of acute upper respiratory infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and auditory functional and anatomical abnormalities in…
- Conditions
- Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection, Otitis Media (OM), Invasive Pneumococcal Disease, Protection Against
- Trial name
- Nunavik2 (NCT01694329)
- Where
- Canada
- Volunteers
- 1,420 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Influenza, Immunosuppression
High Dose vs. Standard Influenza Vaccine in Adult SOT
The study will test whether a high dose influenza vaccination results in improved immunogenicity in adult SOT recipients as compared to standard vaccine.
- Trial name
- NCT03139565
- Testing
- Fluzone High-dose Influenza Vaccine, Standard 2016-2017 Flu vaccine
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- University Health Network, Toronto
Human Volunteers
A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1
This is a first in human, phase I, open label study of the MVA viral vector (produced in the novel immortalised duck retinal cell line AGE1.CR.pIX) expressing the influenza antigens NP and M1 as a fusion protein, in healthy adult…
- Trial name
- NCT03277456
- Testing
- MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza Infection
Efficacy and Safety of Inhaled Peramivir Solution for the Treatment of Adults With Uncomplicated Influenza
This multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 3 study will evaluate the efficacy and safety of peramivir inhalation solution in adults with uncomplicated influenza.
- Trial name
- NCT07791251
- Testing
- Peramivir Inhalation Solution
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Capital Medical University
Influenza
Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood
This is one project of a larger ongoing study related to the immune system's response to the flu virus. This study is designed to determine how immune memory develops at the actual site of exposure, and how immunization may alter…
- Trial name
- FLU-LN (NCT03898973)
- Testing
- Quadrivalent inactivated influenza vaccine (IIV)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension
This study aims to evaluate the tolerability, safety, pharmacokinetic characteristics and efficacy of a single oral dose of GP681 powder for oral suspension in pediatric and adolescent patients with uncomplicated influenza.
- Trial name
- NCT06643156
- Testing
- GP681 10mg/20mg/40mg
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Respiratory Syncytial Virus
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
The purpose of this study is to assess the safety and immunogenicity of RSVpreF when coadministered with SIIV compared to sequential administration of the vaccines when given 1 month apart (SIIV followed by RSVpreF).
- Trial name
- NCT05301322
- Testing
- RSVpreF Vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 33 sites in Australia
- Volunteers
- 1,471 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Immune Responses in Health Care Personnel
This is an investigator-initiated 10 year long open cohort observational study, aiming to increase the understanding of the humoral and cellular immunological mechanisms of vaccination against influenza, including effects of…
- Trial name
- NCT03323112
- Testing
- influenza vaccine
- Where
- Finland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
ARDS, Human, Covid19
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)
A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV…
- Trial name
- RECOVER (NCT04629105)
- Testing
- Longeveron Mesenchymal Stem Cells (LMSCs)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Longeveron Inc.
Influenza Viral Infections
Nasal Swab Home Collection Kit (NSHC Kit) Study
The purpose of this study is to demonstrate that persons over the age of 13 years can obtain a self-collected nasal swab reliably and safely for subsequent use in the diagnosis of influenza.
- Trial name
- NCT03813966
- Testing
- Sofia Influenza A+B FIA
- Where
- 2 sites in United States
- Volunteers
- 1,181 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Flu, Human, Influenza, Human
Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
The aim of the study is to identify what sender/signal combinations are most persuasive in encouraging low socioeconomic males living in the U.S. to take-up seasonal flu vaccination.
- Conditions
- Flu, Human, Influenza, Human, Covid19
- Trial name
- NCT04160975
- Testing
- Video about safety and effectiveness of adult seasonal flu vaccination
- Where
- United States
- Volunteers
- 3,245 people, healthy volunteers welcome
- Sponsor
- Harvard University
Seasonal Influenza
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
A phase III clinical trial of the study of quadrivalent influenza vaccine developed by Sinovac Biotech will be conducted in Chinese children aged 6 to 35 months.
- Trial name
- NCT06049927
- Testing
- Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV)
- Where
- 5 sites in China
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza Like Illness, Asthma
How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice
Previous work has shown that the epidemiological context of a patient's presentation can provide important information for clinicians to aid in diagnosis and treatment.
- Conditions
- Influenza Like Illness, Asthma, Group A Streptococcal Infection, Pertussis
- Trial name
- WGA (NCT01979588)
- Testing
- What's Going Around tool, Control
- Where
- United States
- Volunteers
- 206,703 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Influenza A
Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A
This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.
- Trial name
- NCT03040141
- Testing
- Low dose of VIS410, High dose of VIS410
- Where
- 114 sites in United States, Australia and 18 more
- Volunteers
- 89 people
- Sponsor
- Visterra, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.